---
document_datetime: 2025-01-17 12:15:47
document_pages: 26
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pritor-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: pritor-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 17.7180314
conversion_datetime: 2025-12-20 08:27:45.263664
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pritor

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IG/1812              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                | 07/01/2025                          |                                             | SmPC and PL                      |           |
| WS/2577              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 16/05/2024                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                           |            |            |                           |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|-----------------------------------|
| WS/2489/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 14/09/2023 | 06/09/2024 | SmPC and PL               |                                   |
| PSUSA/2882/ 202203 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                                                                                                                             | 01/12/2022 | n/a        |                           | PRAC Recommendation - maintenance |
| WS/2203            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                             | 03/02/2022 | 05/05/2023 | PL                        |                                   |
| WS/1950            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                            | 26/11/2020 | 26/11/2021 | SmPC, Annex II, Labelling |                                   |

<div style=\"page-break-after: always\"></div>

|                    | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            | and PL              |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------------------|
| IG/1261/G          | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate | 16/07/2020 | n/a        |                     |                                   |
| PSUSA/2882/ 201904 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 28/11/2019 | n/a        |                     | PRAC Recommendation - maintenance |
| PSUSA/2882/ 201804 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 29/11/2018 | n/a        |                     | PRAC Recommendation - maintenance |
| IG/0988            | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                           | 10/10/2018 | n/a        |                     |                                   |
| T/0124             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/03/2018 | 13/04/2018 | SmPC, Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                       |            |            | PL                               |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IG/0904            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                            | 06/02/2018 | 13/04/2018 | Annex II and PL                  |                                   |
| PSUSA/2882/ 201704 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                          | 30/11/2017 | n/a        |                                  | PRAC Recommendation - maintenance |
| WS/1288            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                          | 09/11/2017 | 13/04/2018 | SmPC, Annex II, Labelling and PL |                                   |
| IG/0819            | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                           | 29/06/2017 | n/a        |                                  |                                   |
| PSUSA/2882/ 201604 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                          | 01/12/2016 | n/a        |                                  | PRAC Recommendation - maintenance |
| N/0118             | Update of the package leaflet with revised contact details of the local representative for Portugal. In addition the MAH took the opportunity to make a correction in Section 4 of the Dutch Package Leaflets 20mg, 40mg and 80mg, in line with the EN approved text. | 26/05/2016 | 13/04/2018 | PL                               |                                   |

<div style=\"page-break-after: always\"></div>

|                    | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                    |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------|
| IG/0678            | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 21/04/2016 | n/a        |             |                                                                                                                                    |
| PSUSA/2882/ 201504 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/11/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                                                  |
| N/0116             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/08/2015 | 13/04/2018 | PL          |                                                                                                                                    |
| PSUSA/2882/ 201404 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/11/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                  |
| A31/0106           | On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee (PRAC) to issue a recommendation on the benefit- risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure. | 22/05/2014 | 04/09/2014 | SmPC and PL | For further information please refer to the Renin- angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report. |

<div style=\"page-break-after: always\"></div>

| N/0114   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                     | 14/07/2014   | 13/04/2018   | PL                    |                                                                                                                                                                                                                       |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0570  | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of a revised RMP version 6.0 in order to add \"malignancies\" as an important potential risk. The requested variation worksharing procedure proposed no amendments to the PI. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                      | 26/06/2014   | n/a          |                       | N/A                                                                                                                                                                                                                   |
| WS/0468  | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the Summary of Product Characteristics, Annex II and Package Leaflet. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH | 18/12/2013   | 04/09/2014   | SmPC, Annex II and PL | Update of section 4.8 of the SmPC in order to add dysgeusia as an undesirable effect following CHMP request and assessment of PSUR 12. Furthermore, the PI is updated in line with the latest QRD template version 9. |
| IG/0388  | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                        | 11/12/2013   | 04/09/2014   | Annex II and          |                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2882/ 201304 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 07/11/2013 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| N/0108             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 07/10/2013 | 04/09/2014 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0322            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/07/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| WS/0362            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. The requested variation worksharing procedure proposed amendments to the Summary of Product Characteristics, Annex II, Labelling and Package Leaflet. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 25/04/2013 | 29/05/2013 | SmPC, Annex II, Labelling and PL | For Micardis, Micardis Plus, Kinzalmono, kinzalkomb, Pritor, Pritor Plus Update of sections 4.2, 4.3, 4.4 and 4.5 of the SmPC to implement recommendations regarding the use of telmisartan with aliskiren as requested by the CHMP in the PSUR following the outcome of Article 20 related to aliskiren. In addition, information related to interaction with digoxin is added in section 4.5 of the SmPC. The Package leaflet is updated accordingly. Furthermore, the WSA took the opportunity to sort out a number of inconsistencies in content between SmPCs and PILs for the different products as follows: For Micardis, Micardis Plus, Kinzalmono, kinzalkomb, Pritor, Pritor Plus - Inconsistency between SmPC section 4.5 and PIL regarding interaction with alcohol, barbiturates, narcotics or antidepressants - Inconsistency between SmPC section 4.2 and PIL regarding the storage recommendation. For Twynsta, Onduarp PIL section 4 will be brought in line with SmPC section 4.8 |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                               |            |            |                        | with regard to the side effect hyperglycaemia (amlodipine component) For Micardis Plus, Kinzalkomb, Pritor Plus In the PIL section 2, there is a different wording of telmisartan mono products compared to the telmisartan/HCTZ products for the explanation of cholestasis or biliary obstruction. The MAH proposes to align the wording in the PIL of the telmisartan/HCTZ products so that it is identical with telmisartan mono products. Besides, editorial changes are proposed for Twynsta, Onduarp, Micardis, MicardisPlus, Pritor, PritorPlus, Kinzalmono and Kinzalkomb regarding storage recommendations in Annex IIIA in bold characters to bring them in line with the printing style on the actual, marketed products. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Micardis and Micardis Plus: (Belgium, Bulgaria and Luxembourg, Estonia, Lithuania) Twynsta/Onduarp (Estonia, Belgium and Luxembourg) Furthermore, the WSA proposed this opportunity to bring the PI in line with the latest QRD template   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0254 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 15/11/2012 | 18/12/2012 | SmPC, Labelling and PL | For further information please refer to the variation assessment report: H-000209-WS-0254.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 1901/2006, update of the SmPC in order to include 0502-0403, a study conducted safety, efficacy and pharmacokinetics in the paediatric population. Furthermore, the PI is latest QRD template version corrections were implemented Package Leaflet of Micardis, in sectIn accordance with No 1901/2006, update the SmPC in order to include 0502-0403, a study conducted safety, efficacy and pharmacokinetics in the paediatric population. Furthermore, the Product brought in line with the and minor editorial corrections section 4 of the Package and Kinzalmono, in section and Kinzalmono, and in labelling of Kinzalmono The requested worksharing amendments to the SmPC, Leaflet. ion 6.4 of the SmPC of section 9 of the outer Pritor. The requested worksharing amendments to the SmPC,   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0220 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Following the assessment of PSUR 10 and PSUR 11, update to section 4.4 of the SmPC to include a warning for diabetic patients when treated with insulin or oral antidiabetics and to include a warning on RAAS blockage in patients with uncontrolled blood pressure, and update to section 4.8 of the SmPC to include \"cough\", \"somnolence\" and 'interstitial lung disease' as new ADR and consequential changes to section 4 of the PL. In addition the MAH has aligned the Annexes with version 8 of the QRD template and updated the list of representatives for Micardis only. The MAH also took the opportunity to make some corrections in the EL Annexes for Micardis, BG, CZ, DA, DE, ES, FI, HU, IS, IT, LV, MT, NL, NO, PL, PT, SE, SK, SL Annexes for Kinzalmono, BG, CZ, DA, DE, ES, FI, HU, IS, IT, LV, MT, NL, NO, PL, PT, SE, SK, SL Annexes for Pritor. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article | 19/04/2012 | 25/05/2012 | SmPC, Annex II, Labelling and PL | This type II variation concerns an update of sections 4.4 and 4.8 of the SmPC, upon request by CHMP following the assessment of PSUR 10 and 11, to include a warning for diabetic patients when treated with insulin or oral antidiabetics and to include a warning on RAAS blockage in patients with uncontrolled blood pressure, and to add \"cough\", \"somnolence\" and 'interstitial lung disease' as new ADR. Post-marketing experience with telmisartan has identified 'somnolence', 'cough' and 'interstitial lung disease' as new side effects. Regarding 'diabetic patients', as several patients that developed hypoglycemia were treated with antidiabetics or insulin, the MAH was requested to include a warning to be added in section 4.4 of SmPC in order to advise caution in patient diabetic treated with antidiabetics or insulin. Based on the cases from post marketing experience, the MAH was requested to discuss if an additional recommendation, regarding the dual blockade of the renin angiotensin aldosterone system, should be added to advise caution also in patients with uncontrolled blood pressure. |

<div style=\"page-break-after: always\"></div>

| IG/0165   | B.III.1.a.1 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                                                                                                                                            | 10/04/2012   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0094/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for                                                                                                                                      | 25/08/2011   | n/a        | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| WS/0102   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Summary of Product Characteristics and Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 17/02/2011   | 02/05/2011 | SmPC and PL                      | This type II variation concerns an update of section 4.8 of the SPC to include the ADR 'angioedema (also with fatal outcome)'. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make editorial changes to section 4 in the Package Leaflet and to update the contact details of the Spanish local representative. This application was submitted as a Type II variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. |
| WS/0087/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To add a new alternative manufacturer for the active substance.                                                                                                                                                | 14/04/2011   | 14/04/2011 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | To increase the batch size of the active substance. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0040 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Summary of Product Characteristics and Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 20/01/2011 | 21/02/2011 | SmPC and PL | This type II variation concerns an update of section 4.8 of the SPC, upon request by CHMP following the assessment of PSUR 9, to add further information about 'liver disorder' and to add the ADR 'hypoglycaemia' under post-marketing experience. Most cases of abnormal liver function / liver disorder from post-marketing experience occurred in Japanese patients. The product information has now been updated to reflect the fact that Japanese patients are more likely to experience these adverse reactions. Post-marketing experience with telmisartan has identified hypoglycaemia as a new side effect which occurs mainly in diabetic patients and patients with abnormal glucose tolerance. Based on the statistically significant number of hypoglycaemia reports from pooled clinical trials in hypertensive patients suffering from diabetes, and the cardiovascular outcome trial TRANSCEND, a direct causal relationship between the occurrence of hypoglycaemia in diabetic patients and the therapeutic use of telmisartan cannot be excluded. In addition, the MAH took the opportunity to make changes |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                       |            |            | to the SPC to bring it in line with the latest version of the SPC guideline. The Package Leaflet has been updated accordingly. This application was submitted as a Type II variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0096   | To introduce minor changes in the manufacturing process of the finished product B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions | 17/06/2010 | n/a        |                                                                                                                                                                                                                                                                                              |
| IA/0095/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                | 26/03/2010 | 09/04/2010 |                                                                                                                                                                                                                                                                                              |
| IB/0093   | IB_26_b_Change in the specification of immediate packaging - addition of new test parameter                                                                                                                                                                           | 12/01/2010 | n/a        |                                                                                                                                                                                                                                                                                              |
| IA/0094   | To delete a manufacturing site for an intermediate product IA_09_Deletion of manufacturing site                                                                                                                                                                       | 08/12/2009 | n/a        |                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| IA/0092   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                            | 03/12/2009   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0084   | Extension of Indication                                                                                                                                                                                                                                                     | 22/10/2009   | 23/11/2009 | SmPC and PL                      | Please refer to the assessment report for Pritor EMEA/H/C/000210/0084.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0091   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                                                                                                              | 12/08/2009   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0083   | Update of SPC section 4.8 and 5.1 as well as PL section 4 to add information regarding \"sepsis\" as new side effect. In addition, the MAH took the opportunity to update the List of Local Representatives. Update of Summary of Product Characteristics and Package Leaflet | 23/04/2009   | 26/05/2009 | SmPC and PL                      | In the \"Prevention Regimen For Effectively avoiding Second Strokes\" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 %vs. 0.49 %[RR 1.43 (95 %confidence interval 1.00 - 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95% confidence interval 1.14 - 3.76)]. The observed increased occurrence rate of sepsis associated with the use of telmisartan may be either a chance finding or related to a mechanism not currently known. The term \"sepsis including fatal outcome\" was therefore added to SPC section 4.8 with the frequency unknown and the package leaflet was updated accordingly. |
| T/0088    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                         | 17/04/2009   | 06/05/2009 | SmPC, Annex II, Labelling and PL | The MAH applied for the transfer of the Marketing Authorisation of Pritor from Bayer Healthcare AG to Bayer Schering Pharma AG. The transfer will take place on 15 August 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0089   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                           | 17/04/2009   | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| II/0085   | The MAH applied for an update of the SPC sections 4.3 and 4.6 as well as PL section 2 to implement the CHMP recommendation on a harmonised labelling relating to the use of Angiotensin II Receptor Antagonists during pregnancy and lactation. Furthermore, minor typographical changes have been introduced to SPC section 4.4. Update of Summary of Product Characteristics and Package Leaflet   | 19/02/2009   | 17/03/2009   | SmPC and PL            | Available data regarding use of AIIRAs during lactation have been assessed. There are no concrete data to support the contraindication of use of AIIRAs during breast-feeding. All AIIRA agents were found in the milk of lactating rats but no human data about their transfer into breast milk are available. There is only a theoretical presumption of low transport according to their high plasma protein binding and low oral availability. A harmonised wording recommending an alternative treatment with better established safety profiles during breast-feeding, especially while nursing a newborn or preterm infant, has been included in the section 4.6 of the SPC and section 2 of the PL. Consequently, the existing contraindication for lactation has been deleted.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0086   | IA_29_b_Change in qual./quant. composition of immediate packaging - all other pharm. forms                                                                                                                                                                                                                                                                                                           | 05/02/2009   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0082   | IA_39_Change/addition of imprints, bossing or other markings                                                                                                                                                                                                                                                                                                                                         | 09/12/2008   | n/a          | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0081   | IA_39_Change/addition of imprints, bossing or other markings                                                                                                                                                                                                                                                                                                                                         | 09/12/2008   | n/a          | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0080   | IA_39_Change/addition of imprints, bossing or other markings                                                                                                                                                                                                                                                                                                                                         | 26/11/2008   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| R/0079    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                              | 25/09/2008   | 19/11/2008   | SmPC, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                             |            |            |             | adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Pritor continues to be favourable. The CHMP is also of the opinion that the renewal can be granted with unlimited validity. PSURs will continue to be submitted annually until further notice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0069 | Changes to the test methods and specifications for the finished product Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                      | 25/09/2008 | 02/10/2008 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0071  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                            | 17/07/2008 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0070 | The MAH applied for an update of the SPC sections 4.3, 4.4, and 4.6 as well as PL section 2 to implement the CHMP recommendation on a harmonised labelling relating to the use of ACE inhibitors and Angiotensin II Receptor Antagonists during pregnancy. Update of Summary of Product Characteristics and Package Leaflet | 24/04/2008 | 02/07/2008 | SmPC and PL | Cooper's study published in the NEJM in June 2006 identified a signal of increased risk of congenital malformations, particularly cardiac defects after exposure to ACE inhibitors during the first trimester of pregnancy. Since the role of confounding factors such as diabetes and hypertension cannot be accurately defined based on the available data, the teratogenic potential of ACE inhibitors is not demonstrated, even though data suggest that such exposure cannot be considered as safe and should be avoided. There are fewer data regarding the risks associated with first trimester exposure to Angiotensin II receptor antagonists (AIIRAs) than for ACE inhibitors. Nevertheless, there is no evidence that the risk is lower for AIIRAs, and it is considered that any conclusions on ACE inhibitors are |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            |                           | also valid for AIIRAs. Therefore, the existing contraindication for the 2nd and 3rd trimester of pregnancy remained, but a harmonised wording regarding pregnancy across the class was introduced   |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0078 | IA_09_Deletion of manufacturing site                                                             | 28/05/2008 | n/a        |                           |                                                                                                                                                                                                     |
| IA/0077 | IA_09_Deletion of manufacturing site                                                             | 28/05/2008 | n/a        |                           |                                                                                                                                                                                                     |
| IA/0076 | IA_09_Deletion of manufacturing site                                                             | 28/05/2008 | n/a        |                           |                                                                                                                                                                                                     |
| IA/0075 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                       | 28/05/2008 | n/a        |                           |                                                                                                                                                                                                     |
| IA/0074 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                       | 28/05/2008 | n/a        |                           |                                                                                                                                                                                                     |
| IA/0073 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                       | 28/05/2008 | n/a        |                           |                                                                                                                                                                                                     |
| IA/0072 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                         | 28/05/2008 | n/a        |                           |                                                                                                                                                                                                     |
| IA/0068 | IA_05_Change in the name and/or address of a manufacturer of the finished product                | 10/08/2007 | n/a        |                           |                                                                                                                                                                                                     |
| N/0067  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 27/06/2007 | n/a        | Labelling and PL          |                                                                                                                                                                                                     |
| II/0059 | Update of Summary of Product Characteristics section 4.4 and 4.5 and update Package Leaflet      | 24/01/2007 | 27/02/2007 | SmPC, Annex II, Labelling | The following statement with regards to interaction between NSAIDs and angiotensin II antagonists has been                                                                                          |

<div style=\"page-break-after: always\"></div>

| accordingly with the changes performed on the SPC.                          | and PL   | added to section 4.5 of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------------------------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Update of Summary of Product Characteristics, Labelling and Package Leaflet |          | SPC: \"NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs) may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and the antihypertensive effects of angiotensin II antagonists. In some patients with compromised renal function (eg dehydrated patients or elderly patients with compromised renal function) the co-administration of angiotensin II antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration shoul be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.\" |

<div style=\"page-break-after: always\"></div>

| II/0064   | Change(s) to the manufacturing process for the active substance Change(s) to the manufacturing process for the active substance   | 24/01/2007   | 31/01/2007   |                        |                                                                                                                                                                                                                                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0060   | Update of SPC (4.8) and implementation of MedDRA terminology. Update of Summary of Product Characteristics and Package Leaflet    | 16/11/2006   | 08/01/2007   | SmPC and PL            | Update Section 4.8 of the SPC to add \"acute renal failure, blood creatine phosphokinase increased and hyperkalaemia\". The changes are based either on pharmacological mechanisms and/or on data mining of the company safety database. |
| IB/0066   | IB_33_Minor change in the manufacture of the finished product                                                                     | 18/12/2006   | n/a          |                        |                                                                                                                                                                                                                                        |
| IB/0065   | IB_10_Minor change in the manufacturing process of the active substance                                                           | 09/11/2006   | n/a          |                        |                                                                                                                                                                                                                                        |
| IA/0063   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                           | 17/10/2006   | 17/10/2006   | SmPC, Labelling and PL |                                                                                                                                                                                                                                        |
| IA/0062   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                           | 17/10/2006   | 17/10/2006   | SmPC, Labelling and PL |                                                                                                                                                                                                                                        |
| IA/0061   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                           | 17/10/2006   | 17/10/2006   | SmPC, Labelling and PL |                                                                                                                                                                                                                                        |
| IA/0057   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                  | 08/05/2006   | n/a          |                        |                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| T/0054   | Transfer of Marketing Authorisation                                                                                                                              | 24/02/2006   | 22/03/2006   | SmPC, Labelling and PL   | Transfer from Glaxo Group Limited to Bayer HealthCare AG   |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------------------------------------------|
| IA/0055  | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                 | 20/03/2006   | n/a          | Annex II and PL          |                                                            |
| IA/0052  | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms | 06/02/2006   | n/a          |                          |                                                            |
| IA/0051  | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                 | 06/02/2006   | n/a          | Annex II and PL          |                                                            |
| IA/0053  | IA_36_ b_Change in shape or dimensions of the container/closure - other pharm. forms                                                                             | 01/02/2006   | n/a          |                          |                                                            |
| IA/0050  | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                          | 29/11/2005   | 29/11/2005   | SmPC, Labelling and PL   |                                                            |
| II/0049  | Quality changes                                                                                                                                                  | 17/11/2005   | 24/11/2005   |                          |                                                            |
| IA/0048  | IA_39_Change/addition of imprints, bossing or other markings                                                                                                     | 01/08/2005   | n/a          | SmPC and PL              |                                                            |
| IB/0047  | IB_31_b_Change to in-process tests/limits during manufacture - addition of new tests/limits                                                                      | 20/12/2004   | n/a          |                          |                                                            |
| IB/0046  | IB_25_a_02_Change to comply with Ph. - compliance with EU Ph. - excipient                                                                                        | 20/12/2004   | n/a          |                          |                                                            |

<div style=\"page-break-after: always\"></div>

| II/0044   | Update of Summary of Product Characteristics (4.2, 4.3 and 4.4) and Package Leaflet. Update of Summary of Product Characteristics and Package Leaflet            | 21/10/2004   | n/a        | SmPC and PL                      | The Marketing Authorisation Holder applied for an update to the SPC (sections 4.2, 4.3, 4.4) and subsequent changes to the PL to remove the contraindication and warnings in patients with severe renal impairment (creatinine clearance <30ml/min) based on the results of clinical study 502.339, an open-label, placebo run-in, multicentre study of the efficacy and renal safety of telmisartan 40-80mg once daily for 12 weeks, in patients with all degrees of renal impairment, including patients on haemodialysis. In addition, the postal code has been amended in all Annexes.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0045   | IB_38_c_Change in test procedure of finished product - other changes                                                                                             | 01/10/2004   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0043   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold IA_11_b_Change in batch size of active substance or intermediate - downscaling  | 24/06/2004   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0042   | IA_36_ b_Change in shape or dimensions of the container/closure - other pharm. forms                                                                             | 19/04/2004   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0041   | IB_14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site                                                                | 16/02/2004   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| R/0039    | Renewal of the marketing authorisation.                                                                                                                          | 25/09/2003   | 09/01/2004 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0040   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms | 19/12/2003   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| I/0036   | 01_Change in the name of a manufacturer of the medicinal product                                         | 02/07/2003   | 28/07/2003   | Annex II and PL   |                   |
|----------|----------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-------------------|
| I/0038   | 11_Change in or addition of manufacturer(s) of active substance                                          | 18/07/2003   | 23/07/2003   |                   |                   |
| I/0037   | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance       | 04/07/2003   | 08/07/2003   |                   |                   |
|          | 14_Change in specifications of active substance 24_Change in test procedure of active substance          | 18/06/2003   | 26/06/2003   |                   | I/0035            |
| I/0034   | 12a_Change in specification of starting material/intermediate used in manuf. of the active substance     | 20/06/2003   | 26/06/2003   |                   |                   |
| I/0033   | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance       | 18/06/2003   | 26/06/2003   |                   |                   |
| I/0032   | 20a_Extension of shelf-life or retest period of the active substance                                     | 18/06/2003   | 26/06/2003   |                   |                   |
| I/0031   | 15_Minor changes in manufacture of the medicinal product 16_Change in the batch size of finished product | 16/04/2003   | 02/05/2003   |                   |                   |
| I/0030   | 01_Change in the name of a manufacturer of the medicinal product name of a manufacturer of the           | 16/04/2003   | 02/05/2003   |                   | 11a_Change in the |

<div style=\"page-break-after: always\"></div>

|         | active substance                                                                                     |            |            |                        |
|---------|------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| I/0029  | 32_Change of imprints/bossing/marking on tablets/printing on capsules, incl. addition/change of inks | 13/03/2003 | 26/03/2003 |                        |
| N/0028  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 23/01/2003 | 06/03/2003 | PL                     |
| I/0027  | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process       | 11/11/2002 | 11/12/2002 | Annex II and PL        |
| N/0026  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 19/07/2002 | 22/08/2002 | PL                     |
| I/0025  | 01_Change in the name of a manufacturer of the medicinal product                                     | 23/05/2002 | 07/06/2002 |                        |
| II/0023 | Update of Summary of Product Characteristics and Package Leaflet                                     | 21/02/2002 | 30/05/2002 | SmPC and PL            |
| I/0022  | 30_Change in pack size for a medicinal product                                                       | 23/08/2001 | 16/10/2001 | SmPC, Labelling and PL |
| I/0021  | 20_Extension of shelf-life as foreseen at time of authorisation                                      | 22/08/2001 | n/a        | SmPC                   |
| I/0020  | 04_Replacement of an excipient with a comparable excipient                                           | 04/05/2001 | 11/05/2001 |                        |
| II/0019 | Update of Summary of Product Characteristics and                                                     | 19/10/2000 | 02/02/2001 | SmPC and PL            |

<div style=\"page-break-after: always\"></div>

|         | Package Leaflet                                                                                                                                           |            |            |                        |           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| I/0018  | 15_Minor changes in manufacture of the medicinal product                                                                                                  | 15/08/2000 | n/a        |                        |           |
| I/0017  | 25_Change in test procedures of the medicinal product                                                                                                     | 02/08/2000 | n/a        |                        |           |
| I/0016  | 13_Batch size of active substance                                                                                                                         | 02/08/2000 | n/a        |                        |           |
| I/0015  | 12_Minor change of manufacturing process of the active substance 24a_Change in test procedure for starting material/intermediate used in manuf. of active | 02/08/2000 | n/a        |                        | substance |
| II/0014 | Update of Summary of Product Characteristics and Package Leaflet                                                                                          | 07/04/2000 | 27/07/2000 | SmPC, Labelling and PL |           |
| I/0012  | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance                                                        | 15/03/2000 | 27/03/2000 |                        |           |
| I/0011  | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance                                                        | 15/03/2000 | 27/03/2000 |                        |           |
| I/0009  | 24a_Change in test procedure for starting material/intermediate used in manuf. of active                                                                  | 15/03/2000 | 27/03/2000 |                        | substance |

<div style=\"page-break-after: always\"></div>

| I/0008   | 14_Change in specifications of active substance 12a_Change in specification of starting material/intermediate used in manuf. of the active substance   | 15/03/2000   | 27/03/2000   |                                  |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|
| I/0006   | 20_Extension of shelf-life as foreseen at time of authorisation                                                                                        | 17/12/1999   | 09/03/2000   | SmPC                             |
| I/0010   | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance                                                     | 20/01/2000   | 09/02/2000   |                                  |
| I/0007   | 32_Change of imprints/bossing/marking on tablets/printing on capsules, incl. addition/change of inks                                                   | 17/12/1999   | 22/12/1999   |                                  |
| I/0005   | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                         | 29/10/1999   | 08/11/1999   |                                  |
| X/0001   | X-3-iii_Addition of new strength                                                                                                                       | 20/05/1999   | 16/09/1999   | SmPC, Annex II, Labelling and PL |
| N/0004   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                       | 30/04/1999   | 18/06/1999   | PL                               |
| I/0003   | 15_Minor changes in manufacture of the medicinal product                                                                                               | 19/04/1999   | 26/05/1999   |                                  |
| I/0002   | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                         | 19/04/1999   | 26/05/1999   |                                  |